Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  E. Petricoin,et al.  Proteomic approaches in cancer risk and response assessment. , 2004, Trends in molecular medicine.

[3]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[4]  Mahlon D. Johnson,et al.  Protein Profiling in Brain Tumors Using Mass Spectrometry , 2004, Clinical Cancer Research.

[5]  J. Schellens,et al.  Ras biochemistry and farnesyl transferase inhibitors: a literature survey , 2001, Anti-cancer drugs.

[6]  E. B. Butler,et al.  Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers , 2003, Proteomics.

[7]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[8]  Emanuel F Petricoin,et al.  Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. , 2004, The Journal of urology.

[9]  J. Sebolt-Leopold.  MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. , 2004, Current pharmaceutical design.

[10]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[11]  P. Traxler,et al.  Tyrosine kinases as targets in cancer therapy – successes and failures , 2003, Expert opinion on therapeutic targets.

[12]  L. Liotta,et al.  Use of proteomic analysis to monitor responses to biological therapies , 2004, Expert opinion on biological therapy.

[13]  C. Mirkin,et al.  Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins , 2003, Science.

[14]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[15]  Mauro Ferrari,et al.  Opportunities for Nanotechnology-Based Innovation in Tissue Proteomics , 2004, Biomedical microdevices.

[16]  E. Petricoin,et al.  New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. , 2001, Urology.

[17]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[18]  E. Jaffe,et al.  Molecular Profiling Provides Evidence of Primary Mediastinal Large B-Cell Lymphoma as a Distinct Entity Related to Classic Hodgkin Lymphoma: Implications for Mediastinal Gray Zone Lymphomas as an Intermediate Form of B-Cell Lymphoma , 2004, Advances in anatomic pathology.

[19]  E. Petricoin,et al.  Clinical proteomics: personalized molecular medicine. , 2001, JAMA.

[20]  Emanuel F Petricoin,et al.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.

[21]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[22]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[23]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[24]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[25]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[26]  S. Parsons,et al.  STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor* , 2003, The Journal of Biological Chemistry.

[27]  D. Chan,et al.  Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis , 2003, Annals of surgery.

[28]  E. Petricoin,et al.  Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[30]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[31]  E. Petricoin,et al.  Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.

[32]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[33]  Virginia Espina,et al.  Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. , 2004, Journal of proteome research.

[34]  Dennis C. Sgroi,et al.  Laser Capture Microdissection and Advanced Molecular Analysis of Human Breast Cancer , 2003, Journal of Mammary Gland Biology and Neoplasia.

[35]  E. Petricoin,et al.  Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip , 2000 .

[36]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Emanuel F Petricoin,et al.  Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics , 2004, Proteomics.

[38]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[39]  R. Kurzrock,et al.  Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. , 2005, Annual review of pharmacology and toxicology.

[40]  B. Leyland-Jones,et al.  Optimizing treatment of HER2-positive metastatic breast cancer. , 2004, Seminars in oncology.

[41]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[42]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[43]  P. Cutler.  Protein arrays: The current state‐of‐the‐art , 2003, Proteomics.

[44]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[45]  Virginia Espina,et al.  Protein microarrays: Molecular profiling technologies for clinical specimens , 2003, Proteomics.

[46]  Emanuel F Petricoin,et al.  Serum proteomics in cancer diagnosis and management. , 2004, Annual review of medicine.

[47]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[50]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[51]  S H Moolgavkar,et al.  Mutation and cancer: a model for human carcinogenesis. , 1981, Journal of the National Cancer Institute.

[52]  Yu Shyr,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[53]  E. Petricoin,et al.  Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer , 2004, Clinical Cancer Research.

[54]  Emanuel F. Petricoin,et al.  Biomarker Amplification by Serum Carrier Protein Binding , 2004, Disease markers.

[55]  Baogang J. Xu,et al.  Molecular fingerprinting in human lung cancer. , 2003, Clinical lung cancer.

[56]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[57]  A. Ullrich,et al.  Receptor tyrosine kinases as targets for anticancer drugs. , 2002, Trends in molecular medicine.

[58]  L. Staudt,et al.  Gene expression profiling of lymphoid malignancies. , 2002, Annual review of medicine.

[59]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. Petricoin,et al.  Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. , 2004, Urologic oncology.

[61]  T. Barrette,et al.  Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. , 2001, Cancer research.

[62]  Emanuel F Petricoin,et al.  Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer , 2003, Proteomics.

[63]  N. Katsanis,et al.  Human genetics and disease: Beyond Mendel: an evolving view of human genetic disease transmission , 2002, Nature Reviews Genetics.

[64]  Pascal Furet,et al.  Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.

[65]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[66]  Melanie Hilario,et al.  Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents , 2004, Proteomics.

[67]  J. Hudson,et al.  Development of a prostate cDNA microarray and statistical gene expression analysis package , 2000, Molecular carcinogenesis.

[68]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[69]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[70]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[71]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.